MX2024011415A - Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos. - Google Patents

Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos.

Info

Publication number
MX2024011415A
MX2024011415A MX2024011415A MX2024011415A MX2024011415A MX 2024011415 A MX2024011415 A MX 2024011415A MX 2024011415 A MX2024011415 A MX 2024011415A MX 2024011415 A MX2024011415 A MX 2024011415A MX 2024011415 A MX2024011415 A MX 2024011415A
Authority
MX
Mexico
Prior art keywords
deuterated analogs
erk
intermediates
synthesis
present disclosure
Prior art date
Application number
MX2024011415A
Other languages
English (en)
Spanish (es)
Inventor
Gary Decrescenzo
Martin Teresk
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of MX2024011415A publication Critical patent/MX2024011415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024011415A 2022-03-24 2023-03-24 Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos. MX2024011415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
PCT/US2023/064908 WO2023183905A2 (en) 2022-03-24 2023-03-24 Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
MX2024011415A true MX2024011415A (es) 2024-09-24

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011415A MX2024011415A (es) 2022-03-24 2023-03-24 Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos.

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
IL315702A (en) 2024-11-01
JP2025509969A (ja) 2025-04-11
CA3245978A1 (en) 2023-09-28
WO2023183905A3 (en) 2023-10-26
TW202400572A (zh) 2024-01-01
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
CN119212985A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
EA201290324A1 (ru) Киназные ингибиторы
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
WO2019132560A1 (ko) 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
PH12022553024A1 (en) Inhibitors of nek7 kinase
ZA202400988B (en) Aak1 inhibitor and use thereof
RU2009135621A (ru) Хинолиновые производные для лечения воспалительных заболеваний
SE0400284D0 (sv) Novel compounds
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
SA517381743B1 (ar) مركبات مشتقة من5-[(بيبيرازين-1-يل)]-3-أوكسو-بروبيل]-إيميدازوليدين-2، 4-ديون بصفتها مثبطات adamts لمعالجة الفصال العظمي
TN2012000132A1 (en) N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
EP3870179A1 (en) Usp7 inhibition
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2024011415A (es) Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos.
EA201270266A1 (ru) Гетероциклические соединения
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
MX2025002166A (es) Compuestos y metodos para modular her2
EA200900244A1 (ru) Модуляторы активности хемокиновых рецепторов, их кристаллические формы и способ их получения
NZ767900A (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
EA200900245A1 (ru) Модуляторы активности рецептора хемокина, кристалические формы и способ их получения
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
MX2024007457A (es) Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas.